Edoxaban Tosilate Tablets Patent Linkage Dispute: Determination of Modified Technical Schemes for Generic Drugs

WISECODE Take

Many pharmaceutical companies believe changing a technical scheme after a lawsuit begins cannot reverse the situation. However, this case proves that as long as the drug evaluation authority accepts the new scheme, it becomes the sole benchmark for judging infringement. In the dispute over Edoxaban Tosilate Tablets between a Japanese corporation and Hai Company, CNIPA initially found that the original scheme fell within Claims 2 and 11. However, after Hai Company modified its film coating formula as requested by CDE, the Supreme People's Court ruled that the updated scheme prevailed and found no infringement. This shows that technical modifications by generic drug makers during evaluation provide solid legal defense. For companies with fixed, unchangeable formulations, this ruling has limited impact. Zhidian's Patent Portfolio Checkup service helps businesses re-evaluate infringement risks whenever technical modifications occur. First, retain written proof of acceptance from drug review authorities when altering technical schemes for future litigation. Second, legal teams must re-evaluate patent coverage whenever R&D adjusts formulas or processes. Patent linkage comparison always targets the final product approved for launch, not the initial draft.